XML 185 R131.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details) - Eisai - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative arrangements and non-collaborative arrangement transactions      
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat $ 219.3 $ 348.7 $ 232.0
Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income 109.6 174.3 116.0
Selling, general and administrative | E2609 and BAN2401      
Collaborative arrangements and non-collaborative arrangement transactions      
Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income 4.9 16.2 5.4
Total sales and marketing expense incurred by the collaboration $ 9.8 $ 32.4 $ 10.7